 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
FDA Grants Approval of BMS' Reyataz for Combination Therapy in HIV TreatmentJune 23, 2003 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! The Food and Drug Administration approved Bristol-Myers Squibb Co.'s HIV drug Reyataz (atazanavir), indicated to accompany other antiretroviral agents for the treatment of HIV-1 infection. Reyataz, an azapeptide protease inhibitor, is the first once-daily protease inhibitor approved by the FDA. Data from Phase II and Phase III studies, which collectively enrolled approximately 2,400 HIV patients, showed that, along with sustained virologic suppression, the drug did not significantly increase cholesterol and triglyceride levels when used in combination therapy. "Reyataz brings unique benefits to people living with HIV/AIDS, including the convenience of once-daily dosing and minimal impact on lipid levels," said Peter Dolan, chairman and chief executive officer of BMS. A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
